HALO
Halozyme Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +21.4% ·
share flow +24.3% ·
net new positions +17.6%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 133 | -1 | 91.19M | $6.60B | +6 | −6 |
| Q1 2026 | 136 | +1 | 88.77M | $5.36B | +7 | −7 |
| Q4 2025 | 135 | -1 | 97.38M | $6.16B | +1 | −1 |
| Q3 2025 | 22 | +1 | 49.86M | $3.66B | +1 | −1 |
| Q2 2025 | 19 | 0 | 43.24M | $2.25B | — | — |
| Q1 2025 | 16 | -1 | 15.61M | $996.39M | — | −1 |
| Q4 2024 | 17 | +3 | 17.59M | $840.95M | +4 | −1 |
| Q3 2024 | 13 | -1 | 6.97M | $398.81M | — | −1 |
| Q2 2024 | 14 | — | 8.14M | $426.06M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 7.18M | — | $343.50M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passive) | 3.06M | +0.1% | $146.53M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 1.26M | New | $60.37M | 0.1% | New | 1 | SEC ↗ ×3 |
| 4 | Norges Bank ✦ (passive) | 1.26M | +15.2% | $60.05M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.22M | -4.1% | $58.25M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 6 | Arrowstreet Capital ✦ | 992.89K | +141.3% | $47.47M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 831.41K | +171.2% | $39.75M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 8 | Capital World Investors ✦ | 748.23K | New | $35.77M | 0.0% | New | 1 | SEC ↗ |
| 9 | Fisher Asset Management ✦ | 414.72K | +28.0% | $19.83M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 247.03K | +403.0% | $11.81M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Millennium Management ✦ | 95.42K | +254.5% | $4.56M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 12 | Point72 Asset Management ✦ | 84.83K | New | $4.06M | 0.0% | New | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 57.37K | -11.9% | $2.74M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 14 | AQR Capital Management ✦ | 52.96K | +0.8% | $2.53M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 15 | Gotham Asset Management ✦ | 47.44K | +9.7% | $2.27M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 26.11K | -89.8% | $1.25M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Marshall Wace ✦ | 4.43K | New | $211,607 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $60.37M | 0.1% |
| Capital World Investors | $35.77M | 0.0% |
| Point72 Asset Management | $4.06M | 0.0% |
| Marshall Wace | $211,607 | 0.0% |
Exited
| Bridgewater Associates | $659,119 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 8 holders, 32.79M shares, $43.93M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 200 sh · $22,102
Officer, Director · 11.90K sh · $1.31M
Officer, Director · 3.09K sh · $336,526
Officer, Director · 4.81K sh · $520,341
Officer, Director · 8.60K sh · $954,867
Officer, Director · 200 sh · $22,739
Officer, Director · 900 sh · $101,502
Officer, Director · 10.30K sh · $1.15M
Officer, Director · 1.78K sh · $197,245
Officer, Director · 9.92K sh · $1.09M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology